A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction

被引:666
作者
Yawn, Barbara P.
Saddier, Patricia
Wollan, Peter C.
Sauver, Jennifer L. St.
Kurland, Marge J.
Sy, Lina S.
机构
[1] Olmsted Med Ctr, Res Dept, Rochester, MN USA
[2] Merck Res Labs, Dept Epidemiol, N Wales, PA USA
[3] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA
关键词
D O I
10.4065/82.11.1341
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: To establish accurate, up-to-date, baseline epidemiological data for herpes zoster (HZ) before the introduction of the recently licensed HZ vaccine. METHODS: Using data from January 1, 1996, to October 15, 2005, we conducted a population-based study of adult residents (222 years) of Olmsted County, MN, to determine (by medical record review) the incidence of HZ and the rate of HZ-related complications. Incidence rates were determined by age and sex and adjusted to the US population. RESULTS: A total of 1669 adult residents with a confirmed diagnosis of HZ were identified between January 1, 1996, and December 31, 2001. Most (92%) of these patients were immunocompetent and 60% were women. When adjusted to the US adult population, the incidence of HZ was 3.6 per 1000 person-years (95% confidence interval, 3.4-3.7), with a temporal increase from 3.2 to 4.1 per 1000 person-years from 1996 to 2001. The incidence of HZ and the rate of HZ-associated complications increased with age, with 68% of cases occurring in those aged 50 years and older. Postherpetic neuralgia occurred in 18% of adult patients with HZ and in 33% of those aged 79 years and older. Overall, 10% of all patients with HZ experienced 1 or more nonpain complications. CONCLUSIONS: Our population-based data suggest that HZ primarily affects immunocompetent adults older than 50 years; 1 in 4 experiences some type of HZ-related complication.
引用
收藏
页码:1341 / 1349
页数:9
相关论文
共 53 条
[1]   Treatment of postherpetic neuralgia: A review of therapeutic options [J].
Argoff, CE ;
Katz, N ;
Backonja, M .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2004, 28 (04) :396-411
[2]  
Brisson M., 2003, Journal of Medical Virology, V70, pS9, DOI 10.1002/jmv.10313
[3]   Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox [J].
Brisson, M ;
Gay, NJ ;
Edmunds, WJ ;
Andrews, NJ .
VACCINE, 2002, 20 (19-20) :2500-2507
[4]   The cost-effectiveness of varicella vaccination in Canada [J].
Brisson, M ;
Edmunds, WJ .
VACCINE, 2002, 20 (7-8) :1113-1125
[5]   Modelling the impact of immunization on the epidemiology of varicella zoster virus [J].
Brisson, M ;
Edmunds, WJ ;
Gay, NJ ;
Law, B ;
De Serres, G .
EPIDEMIOLOGY AND INFECTION, 2000, 125 (03) :651-669
[6]   Epidemiology of varicella zoster virus infection in Canada and the United Kingdom [J].
Brisson, M ;
Edmunds, WJ ;
Law, B ;
Gay, NJ ;
Walld, R ;
Brownell, M ;
Roos, L ;
De Serres, G .
EPIDEMIOLOGY AND INFECTION, 2001, 127 (02) :305-314
[7]   The management of post-herpetic neuralgia - If early treatment fails, patients should be referred to pain clinics [J].
Cunningham, AL ;
Dworkin, RH .
BRITISH MEDICAL JOURNAL, 2000, 321 (7264) :778-779
[8]  
Czernichow S, 2001, ANN DERMATOL VENER, V128, P497
[9]   THE OUTCOME OF PATIENTS WITH HERPES ZOSTER [J].
DEMORAGAS, JM ;
KIERLAND, RR .
ARCHIVES OF DERMATOLOGY, 1957, 75 (02) :193-194
[10]   THE INCIDENCE OF HERPES-ZOSTER [J].
DONAHUE, JG ;
CHOO, PW ;
MANSON, JE ;
PLATT, R .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (15) :1605-1609